Compare CFFN & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | COLL |
|---|---|---|
| Founded | 1893 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 981.1M | 1.1B |
| IPO Year | 2010 | 2015 |
| Metric | CFFN | COLL |
|---|---|---|
| Price | $8.07 | $34.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.25 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 605.2K | 332.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | 0.32 | ★ 0.40 |
| Revenue | $16,300,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $20.16 | $8.01 |
| Revenue Next Year | $6.62 | N/A |
| P/E Ratio | ★ $25.22 | $87.00 |
| Revenue Growth | 6.54 | ★ 23.62 |
| 52 Week Low | $5.71 | $29.08 |
| 52 Week High | $8.13 | $50.79 |
| Indicator | CFFN | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 55.48 |
| Support Level | $7.49 | $34.03 |
| Resistance Level | N/A | $35.95 |
| Average True Range (ATR) | 0.14 | 1.12 |
| MACD | 0.03 | 0.26 |
| Stochastic Oscillator | 88.99 | 86.33 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.